17 results
8-K
EX-99.1
CRGX
CARGO Therapeutics Inc
14 May 24
CARGO Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
4:09pm
, and manufacturing strategy are designed to directly address the limitations of approved cell therapies, including limited durability of effect, safety concerns
DEF 14A
CRGX
CARGO Therapeutics Inc
24 Apr 24
Definitive proxy
4:27pm
risk management into our corporate strategy and day-to-day business operations. Management discusses strategic and operational risks at regular
10-K
2023 FY
CRGX
CARGO Therapeutics Inc
21 Mar 24
Annual report
4:21pm
, including, without limitation, statements regarding our strategy, future operations, future operating expenses, future financial position, future … to adopt a Risk Evaluation and Mitigation Strategy;
our commercialization, marketing and manufacturing, including the buildout of our own manufacturing
8-K
EX-99.1
CRGX
CARGO Therapeutics Inc
21 Mar 24
CARGO Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
4:10pm
technologies, and manufacturing strategy are designed to directly address the limitations of approved cell therapies, including limited durability
8-K
EX-99.1
d73md q5v3
8 Jan 24
Regulation FD Disclosure
6:11am
8-K
EX-99.1
a2diwros9 4z7o
13 Dec 23
CARGO Therapeutics Reports Business Updates and Third Quarter 2023 Results
5:22pm
10-Q
qxwh0qep k0on7
13 Dec 23
Quarterly report
4:31pm
424B4
mg9sbxeivs
13 Nov 23
Prospectus supplement with pricing info
4:31pm
S-1
f6v gpagcy3i0re
20 Oct 23
IPO registration
4:07pm
S-1
EX-10.10
klq8l6gxv4ce094 eoos
20 Oct 23
IPO registration
4:07pm
S-1
EX-10.1
tyay19rszrq72g3x
20 Oct 23
IPO registration
4:07pm
DRS/A
vo9zeuuxmz8irze u5j5
4 Oct 23
Draft registration statement (amended)
12:00am
DRS
mkmne
1 Sep 23
Draft registration statement
12:00am
- Prev
- 1
- Next